These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 8212320)
41. Review of the Drug Trials Snapshots Program of the US Food and Drug Administration: Women in Cardiovascular Drug Trials. Whyte J; Woodcock J; Wang J JAMA Intern Med; 2017 May; 177(5):724-727. PubMed ID: 28288256 [TBL] [Abstract][Full Text] [Related]
43. Novel players in cardioprotection: Insulin like growth factor-1, angiotensin-(1-7) and angiotensin-(1-9). Westermeier F; Bustamante M; Pavez M; García L; Chiong M; Ocaranza MP; Lavandero S Pharmacol Res; 2015 Nov; 101():41-55. PubMed ID: 26238180 [TBL] [Abstract][Full Text] [Related]
44. The complications of cardiovascular aging. Gawlinski A; Jensen GA Am J Nurs; 1991 Nov; 91(11):26-30. PubMed ID: 1951491 [No Abstract] [Full Text] [Related]
45. Clinical trials in cardiovascular medicine: are we looking for statistical significance or clinical relevance? Willenheimer R; Dahlöf B; Gordon A Heart; 2000 Aug; 84(2):129-33. PubMed ID: 10908243 [No Abstract] [Full Text] [Related]
46. Design of multifunctional compounds for cardiovascular disease: from natural scaffolds to "classical" multitarget approach. Bisi A; Gobbi S; Belluti F; Rampa A Curr Med Chem; 2013; 20(13):1759-82. PubMed ID: 23410171 [TBL] [Abstract][Full Text] [Related]
48. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders. Henning RJ; Bourgeois M; Harbison RD Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072 [TBL] [Abstract][Full Text] [Related]
49. [Chalcones (1,3-diarylpropen-1-ones) and their analogs as potential therapeutic agents in cardiovascular system diseases]. Opletalová V; Jahodár L; Jun D; Opletal L Ceska Slov Farm; 2003 Jan; 52(1):12-9. PubMed ID: 12685329 [TBL] [Abstract][Full Text] [Related]
50. Viewpoint: an explanation for the cardiovascular effects of bevacizumab and rofecoxib? Barnard K Circulation; 2006 Nov; 114(19):f173-5. PubMed ID: 17088471 [No Abstract] [Full Text] [Related]
51. Minority underrepresentation in cardiovascular outcome trials for type 2 diabetes. Hoppe C; Kerr D Lancet Diabetes Endocrinol; 2017 Jan; 5(1):13. PubMed ID: 28010783 [No Abstract] [Full Text] [Related]
52. European Society of Cardiology--2009 annual congress. 31 August - 2 September 2009, Barcelona, Spain. Wong NC IDrugs; 2009 Nov; 12(11):675-8. PubMed ID: 19844849 [TBL] [Abstract][Full Text] [Related]
54. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. Balakumar P; Dhanaraj SA Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531 [TBL] [Abstract][Full Text] [Related]
55. Eplerenone for the treatment of cardiovascular disorders. Watanabe M; Krum H Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915 [TBL] [Abstract][Full Text] [Related]
56. [Cardiovascular pharmacology in the 90s: where are we?]. Marín Huerta E; Rayo I Rev Esp Cardiol; 1994 Jun; 47(6):390-402. PubMed ID: 8066311 [No Abstract] [Full Text] [Related]
57. The physiological response to cardiovascular 'orphan' G protein-coupled receptor agonists. Hare JM; Kass DA; Stamler JS Nat Med; 1999 Nov; 5(11):1241-2. PubMed ID: 10545987 [TBL] [Abstract][Full Text] [Related]